Details
Stereochemistry | ACHIRAL |
Molecular Formula | CO3.2Fe.4Mg.12HO.4H2O |
Molecular Weight | 545.068 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Fe+3].[Fe+3].[O-]C([O-])=O
InChI
InChIKey=VESOWWBEYMMDFG-UHFFFAOYSA-A
InChI=1S/CH2O3.2Fe.4Mg.16H2O/c2-1(3)4;;;;;;;;;;;;;;;;;;;;;;/h(H2,2,3,4);;;;;;;16*1H2/q;2*+3;4*+2;;;;;;;;;;;;;;;;/p-14
Molecular Formula | Mg |
Molecular Weight | 24.305 |
Charge | 2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Fe |
Molecular Weight | 55.845 |
Charge | 3 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CH2O3 |
Molecular Weight | 62.0248 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | H2O |
Molecular Weight | 18.0153 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
FERMAGATE is a phosphate binder with phosphate plasma levels lowering activity. It is in Phase 3 development in the US and in Europe for the treatment of hyperphosphatemia in dialysis patients. It is made up of magnesium and ferric iron atoms held in an insoluble, rigid, crystalline-layered structure, with carbonate groups lying between the layers. Upon oral administration, the carbonate ions in FERMAGATE are exchanged for free phosphate ions released from food in the gastrointestinal tract; thereby, strongly binding phosphate. This inhibits phosphate uptake and preventing hyperphosphatemia.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25815172
Recommended daily dose: 3000 mg, three pills per day.
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 16 19:22:40 UTC 2022
by
admin
on
Fri Dec 16 19:22:40 UTC 2022
|
Record UNII |
LH78JQC1MP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C78275
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
C81345
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
PRIMARY | |||
|
SUB126750
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
PRIMARY | |||
|
C541219
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
PRIMARY | |||
|
DTXSID70152328
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
PRIMARY | |||
|
8948
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
PRIMARY | |||
|
LH78JQC1MP
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
PRIMARY | |||
|
71491874
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
PRIMARY | |||
|
119175-48-3
Created by
admin on Fri Dec 16 19:22:41 UTC 2022 , Edited by admin on Fri Dec 16 19:22:41 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ANHYDROUS->SOLVATE | |||
|
PARENT -> SALT/SOLVATE |